Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01205646 · ClinicalTrials.gov registry record · NA

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer

A NA study of Prostate Cancer, sponsored by Barbara Ann Karmanos Cancer Institute.

Completed
Registry status
NA
Development phase
11
Enrollment target
2
Study locations

NCT01205646 is a NA study of Prostate Cancer that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 11 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01205646, a NA study of Prostate Cancer, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.

COMPLETED
Registry status
NA
Development phase
11 participants
Enrollment target
2
Study locations

Study Summary

The primary goal for this trial is to assess the change in PET scans with the administration of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer. It has been established that zoledronate therapy may play a role in delaying and reducing the incidence of skeletal events. Researchers propose to evaluate the change in the uptake value of FMAU PET scan after the zoledronate therapy. It has been demonstrated that FMAU PET scans can successfully demonstrate and detect bony metastatic sites in prostate cancer. In addition, investigators would like to evaluate the change in the level of the prostate-specific antigen (PSA) in the patient as well as outcome of bone scans.

Conditions Studied

Prostate Cancer

Interventions

  • DEVICE PET Scan
  • DRUG zoledronate therapy

Study Locations (2)

Michigan

  • Barbara Ann Karmanos Cancer Institute - Detroit
  • Karmanos Cancer Institute Weisberg Cancer Treatment Center - Farmington Hills

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2010-09
Est. Completion 2015-08
Phase NA

Sponsor

Barbara Ann Karmanos Cancer Institute

139 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01205646

The ClinicalTrials.gov registry entry for NCT01205646 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which PET Scan is the first listed.

NCT01205646 reports 2 study locations spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT01205646 about?

NCT01205646 is a clinical study titled "PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer". The primary goal for this trial is to assess the change in PET scans with the administration of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer. It has been established that zoledronate therapy may play a role in delaying and reducing the incidence of skeletal events...

What is the current status of trial NCT01205646?

This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2010-09. Estimated completion is 2015-08.

What conditions does trial NCT01205646 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT01205646?

The interventions under investigation include: PET Scan (DEVICE), zoledronate therapy (DRUG).

Who is sponsoring clinical trial NCT01205646?

This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01205646 being conducted?

This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.